Lundbeck research director after double fiasco: We have much more interesting assets to work on
Although research director Johan Luthman is disappointed that Parkinson's drug foliglurax has performed so badly in clinical trials that the project is being shut down, he still sees lots of potential in the newly-purchased Abide portfolio - though this has also included one fiasco.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.